Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Importance of real-world data on patient outcomes

Vimalanand Prabhu • 26 Oct 2021
ESGO 2021
Endometrial Cancer General Gynecological Cancer

Vimalanand Prabhu, PhD, Merck, Lansdale, PA, discusses possible sources and uses of real-world data, and compares this style of study to randomized clinical trials. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

Disclosures

Vimalanand Prabhu is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and shareholder of Merck & Co., Inc., Kenilworth, NJ, USA.

More from Vimalanand Prabhu

3:24
Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer
Vimalanand Prabhu • 26 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals